Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
March 28, 2024 07:55 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
March 27, 2024 08:05 ET
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
November 09, 2023 08:00 ET
|
Aeterna Zentaris Inc
- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
July 13, 2023 07:30 ET
|
Aeterna Zentaris Inc
Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
March 16, 2023 08:05 ET
|
Aeterna Zentaris Inc
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023 08:05 ET
|
Aeterna Zentaris Inc
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
November 03, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 ...
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 05, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets – Pivotal Phase 3 DETECT (Study P02)...
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
February 16, 2021 17:19 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...